menu
    • menu

    Company profile for Arialys Therapeutics

    NEW Drugs in Dev: 1
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Arialys Therapeutics is a developer of new precision medicines to specifically block pathogenic autoantibodies in the brain. The company specializes in the field of neuroscience and characterizes the nature and prevalence of pathogenic auto-antibody activity in the central nervous system converged network services, providing the healthcare industry with advanced breakthrough therapies for a variety of central nervous system di...
    Arialys Therapeutics is a developer of new precision medicines to specifically block pathogenic autoantibodies in the brain. The company specializes in the field of neuroscience and characterizes the nature and prevalence of pathogenic auto-antibody activity in the central nervous system converged network services, providing the healthcare industry with advanced breakthrough therapies for a variety of central nervous system disorders and treating neuropsychiatric disorders driven by autoimmune diseases.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Arialys TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    11099 NORTH TORREY PINES RD SUITE 290 LA JOLLA, CA 92037
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.arialysrx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/arialys-therapeutics-inc/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    IPhEB Russia

    Not Confirmed

    envelop Contact Supplier

    IPhEB Russia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Arialys Therapeutics Gets Rare Pediatric Disease Nod For ART5803
    Arialys Therapeutics Gets Rare Pediatric Disease Nod For ART5803

    25 Sep 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250925402809/en/Arialys-Therapeutics-Receives-FDA-Rare-Pediatric-Disease-Designation-for-ART5803-to-Treat-Anti-NMDA-Receptor-Encephalitis

    BUSINESSWIRE
    25 Sep 2025
    Share Share
    Arialys Presents Promising Data for IgG1 Antibody Treatment
    Arialys Presents Promising Data for IgG1 Antibody Treatment

    21 Jun 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/research/arialys-therapeutics-precision-therapy-shows-promise-rare-encephalitis-disorder-and-beyond

    FIERCE BIOTECH
    21 Jun 2025
    Share Share
    Arialys Shows ART5803 Efficacy In Autoimmune Disorder
    Arialys Shows ART5803 Efficacy In Autoimmune Disorder

    17 Jun 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250606272099/en/Arialys-Therapeutics-Publishes-Preclinical-Data-in-Nature-Communications-Supporting-ART5803-as-a-First-in-Class-Precision-Therapeutic-for-Anti-NMDA-Receptor-Autoimmune-Neuropsychiatric-Disease

    BUSINESSWIRE
    17 Jun 2025
    Share Share
    Arialys Starts MAD Cohorts In Ph 1 Study For Autoimmune Disease
    Arialys Starts MAD Cohorts In Ph 1 Study For Autoimmune Disease

    26 Feb 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250221718418/en

    BUSINESSWIRE
    26 Feb 2025
    Share Share
    Arialys Appoints Sankalp Gokhale As Chief Medical Officer
    Arialys Appoints Sankalp Gokhale As Chief Medical Officer

    22 Oct 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241022809435/en

    BUSINESSWIRE
    22 Oct 2024
    Share Share
    Arialys Therapeutics Doses First Participants In ART5803 Trial
    Arialys Therapeutics Doses First Participants In ART5803 Trial

    10 Oct 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241007735228/en

    BUSINESSWIRE
    10 Oct 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search